Who are Cytotronics's investors?

Cytotronics's investors include Anzu Partners, LYFE Capital, Bantam Group, Draper Associates, BoxOne Ventures.

How much funding has Cytotronics raised?

Cytotronics has disclosed $13.5M raised across 1 round.

Who acquired Cytotronics?

Cytotronics was acquired by Axion BioSystems.

Where is Cytotronics headquartered?

Cytotronics is headquartered in Boston, US.

Cytotronics

acquired by Axion BioSystems

Boston, US · Founded 2020 · Delaware corporation · 8 employees on LinkedIn · 5 known investors

Find your way into Cytotronics

Paths you didn't know you had: your email and LinkedIn already hold routes to the Cytotronics team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Acquired by Axion BioSystems January 2026 · terms undisclosed · source ↗

Cytotronics develops Pixel, a semiconductor-to-live-cell interface platform that measures cell viability, morphology, electrophysiology, and metabolism at single-cell resolution across any cell type or 3D organoid system. It serves cell biologists working in therapeutic areas such as vascular biology, stem cell differentiation, cardiovascular and neurological disease, and oncology.

Biotech Deep Tech Semiconductors

Founders & leadership

Cytotronics was founded in 2020 by Jeffrey Abbott, Duane Sword, Donhee Ham, Hongkun Park, and Vince (Wenxuan) Wu.

Jeffrey Abbott Co-Founder & CEO2021–2026Jeffrey Abbott co-founded Cytotronics based on CMOS nanoelectrode array research conducted at Harvard, scaling the company to over 25 employees and $24M in funding before its acquisition by Axion BioSystems in 2026, where he now serves as Vice President of Emerging Technologies. His background spans semiconductor design, bioelectronic interface development, and commercialization of life science instrumentation.

Duane Sword Co-Founder & CBODuane Sword has held executive roles at publicly-traded life sciences companies including Agilent Technologies and Thermo Fisher Scientific, as well as leadership positions (CEO, CBO, VP Sales) at private ventures including Ahura Scientific, Precisive, and RedWave Technology. As Co-founder and CBO of Cytotronics, he raised $25M for the company's semiconductor-to-live-cell interface platform before its acquisition by Axion Biosystems in 2026.

Donhee HamScientific Co-Founder

Hongkun ParkScientific Co-Founder

Vince (Wenxuan) WuCo-founder & CTO (Acquired by Axion Biosystems)2021–2025

Wenxuan WuNamed on SEC filing

Board

Sameer Rohatgi Member Board of Directors2024–2026Partner at LYFE Capital

Jenna Abelli Board Member2021–2026Principal, Investment at Anzu Partners

Douglas KahnBoard director

Investors · 5

Anzu Partners✓ confirmed by CytotronicsBillerica

How we know: Anzu Partners's portfolio page · the company's own site · Not right? Tell us

LYFE Capital✓ confirmed by CytotronicsMenlo Park

How we know: the company's own site · Not right? Tell us

Bantam Grouplisted by Bantam GroupWestwood

How we know: the VCSheet dataset · Not right? Tell us

Draper Associateslisted by Draper AssociatesSan Mateo · $500K – $5M

How we know: Draper Associates's portfolio page · Not right? Tell us

BoxOne VenturesreportedMontréal · $500K

How we know: the VCSheet dataset · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$13.5M disclosed across 1 round · 2024

▶$13.5MraisedOct 2024 · 10 investors · Other Technology

Rule 506(b)

Officers, directors & promoters on the filing

Sameer RohatgiDirector
Jeffrey AbbottExecutive Officer, Director
Douglas KahnDirector
Wenxuan WuExecutive Officer, Director
Jenna AbelliDirector

Offering amount: $13.5M
Amount sold: $13.5M
First sale: Mar 2024
Incorporated: Corporation, Delaware, 2020
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 1

Molecular DevicesMolecular Devices provides automated systems and services to support 3D cell biology research workflows, including cell culture automation, organoid expansion services, and imaging analysis tools for drug discovery and preclinical research.

Companies working in the same space as Cytotronics.

Frequently asked questions

What does Cytotronics do?: Cytotronics develops Pixel, a semiconductor-to-live-cell interface platform that measures cell viability, morphology, electrophysiology, and metabolism at single-cell resolution across any cell type or 3D organoid system. It serves cell biologists working in therapeutic areas such as vascular biology, stem cell differentiation, cardiovascular and neurological disease, and oncology.
Who founded Cytotronics?: Cytotronics was founded by Jeffrey Abbott, Duane Sword, Donhee Ham, Hongkun Park, Vince (Wenxuan) Wu in 2020.
Who are Cytotronics's investors?: Cytotronics's investors include Anzu Partners, LYFE Capital, Bantam Group, Draper Associates, BoxOne Ventures.
How much funding has Cytotronics raised?: Cytotronics has disclosed $13.5M raised across 1 round.
Who acquired Cytotronics?: Cytotronics was acquired by Axion BioSystems.
Where is Cytotronics headquartered?: Cytotronics is headquartered in Boston, US.